Panorbis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 288.04%
- Profit Growth -91.22%
- Ebitda -91.19%
- Net Worth -1532.03%
- Total Assets 22.24%
About Panorbis Lifesciences
Panorbis Lifesciences Private Limited (PLPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 July 2014 and has a history of Ten years and seven months. Its registered office is in Nagpur, Maharashtra.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Shahnawaz Siddiqui, Nokesh Wadhai, and Sanjiv Bais serve as directors at the Company.
Company Details
- Location Nagpur, Maharashtra
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999MH2014PTC256095
- Company No.
256095
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 2014
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Panorbis Lifesciences Private Limited offer?
Panorbis Lifesciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Panorbis Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shahnawaz Siddiqui  | Director | 17-Jul-2014 | Current |
| Nokesh Wadhai | Director | 17-Jul-2014 | Current |
| Sanjiv Bais | Director | 17-Jul-2014 | Current |
Financial Performance of Panorbis Lifesciences.
Panorbis Lifesciences Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 288.04% increase. The company also saw a substantial fall in profitability, with a 91.22% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1532.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Panorbis Lifesciences?
In 2016, Panorbis Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Panorbis Lifesciences?
Unlock and access historical data on people associated with Panorbis Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Panorbis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Panorbis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
